GlassScriptPhysician profile
Amanda Jo Johnson
NPI 1891457289
$1,052.10
in general payments reported to CMS, 2019-2025
16 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $133 · 2024: $455 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.02 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148.97 | 2025 | |
| Nxstage Medical, INC. | $145.19 | 2024 | |
| Pulmonx Corporation | $142.83 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Fresenius USA Marketing, INC. | $138.20 | 2023-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $96.57 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $78.10 | 2022-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $70.61 | 2023-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $61.41 | 2023-2025 | |
| Boston Scientific Corporation | $35.32 | 2025 | Watchman Flx |
| Daiichi Sankyo INC. | $33.34 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $23.78 | 2022 | |
| Calliditas Therapeutics US INC. | $16.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.62 | 2024 | Alunbrig |
| Opko Pharmaceuticals, LLC | $16.21 | 2022 | |
| Horizon Therapeutics Plc | $14.37 | 2023 | Krystexxa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.